GE HealthCare recalled 45 dual-head nuclear medicine gamma cameras on September 12, 2025. The recall affects devices that may have been relocated without proper support, risking a detector fall. This defect can lead to life-threatening injuries.
GE HealthCare has become aware that certain Nuclear Medicine systems that are past the End of Guaranteed Service could have been transported or relocated without adequate detector support. This could result in excessive stress being applied to the detector mounting mechanisms, compromising their integrity. If this occurs, it can potentially result in a detector fall and lead to life-threatening bodily injury.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact GE MEDICAL SYSTEMS ISRAEL, FUNCTIONAL IMAGING or your healthcare provider for instructions. Notification method: Letter
The recall involves all serial numbers of the Elscint SPX4 nuclear medicine gamma camera. These devices were distributed worldwide.
The gamma cameras may have been transported without adequate detector support. This can stress the mounting mechanisms, risking a fall of the detector and potentially causing severe injuries.
No specific incidents have been reported yet, but the hazard poses a high risk of life-threatening injury.
Stop using the gamma camera immediately. Follow the recall instructions provided by GE HealthCare and contact your healthcare provider.
For more information, contact GE Medical Systems Israel, Functional Imaging. Visit the FDA recall webpage for updates.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.